Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Total revenues	$ 12,319	$ 13,538	$ 27,901	$ 27,580
Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,076	6,058	6,913	9,655
EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,741	3,808	12,466	8,800
APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	3,502	3,672	8,522	9,125
Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	6,249	3,723	14,236	9,886
Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	6,070	9,815	13,665	17,694
Performance Enzymes [Member]
Disaggregation of Revenue [Line Items]
Total revenues	10,589	11,165	20,676	21,894
Performance Enzymes [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,076	6,058	6,913	9,655
Performance Enzymes [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	3,011	1,435	5,241	3,114
Performance Enzymes [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	3,502	3,672	8,522	9,125
Performance Enzymes [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	6,249	3,723	14,236	9,886
Performance Enzymes [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,340	7,442	6,440	12,008
Novel Biotherapeutics [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,730	2,373	7,225	5,686
Novel Biotherapeutics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,730	2,373	7,225	5,686
Novel Biotherapeutics [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,730	$ 2,373	$ 7,225	$ 5,686